All Stories

  1. Primary Sjögren’s Syndrome and Cardiovascular Disease
  2. p38 mitogen‐activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg‐negative chronic hepatitis B
  3. A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic sclerosis
  4. Dietary management of celiac disease: Revisiting the guidelines
  5. TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort
  6. Porphyromonas gingivalis and rheumatoid arthritis
  7. A Systematic Review of Medical Nutrition Therapy Guidelines for Liver Cirrhosis: Do We Agree?
  8. On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells
  9. Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
  10. Correction to: A proteome-wide immuno-mass spectrometric identification of serum autoantibodies
  11. Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer’s Disease Risk?
  12. Nutrition Interventions in Pediatric Pancreatitis
  13. Targeting very early systemic sclerosis: a case-based review
  14. A proteome-wide immuno-mass spectrometric identification of serum autoantibodies
  15. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis
  16. Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases
  17. Anti‐C1q autoantibodies are frequently detected in patients with systemic sclerosis associated with pulmonary fibrosis
  18. ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population
  19. Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?
  20. Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn’s Disease
  21. Tryptophan-kynurenine profile in pediatric autoimmune hepatitis
  22. Cancer-associated stroke: Pathophysiology, detection and management (Review)
  23. Paraoxonase-1 genetic polymorphisms in organophosphate metabolism
  24. Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis
  25. H. pylori and Parkinson’s disease: Meta-analyses including clinical severity
  26. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  27. Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
  28. Replication study of GWAS risk loci in Greek multiple sclerosis patients
  29. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
  30. AGREEing on Guidelines for Nutrition Management of Adult Severe Burn Patients
  31. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype
  32. Curcumin for the Management of Periodontitis and Early ACPA-Positive Rheumatoid Arthritis: Killing Two Birds with One Stone
  33. Multiple hit infection and autoimmunity
  34. The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?
  35. IL-35: a new immunomodulator in autoimmune rheumatic diseases
  36. CpG Island Methylation Patterns in Relapsing-Remitting Multiple Sclerosis
  37. Interaction between microbiome and host genetics in psoriatic arthritis
  38. The Role of Flavonoids in Inhibiting Th17 Responses in Inflammatory Arthritis
  39. IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells
  40. IL-10-producing regulatory B cells (B10 cells), IL-17 + T cells and autoantibodies in systemic sclerosis
  41. Vitamin B12, folate, and homocysteine levels and multiple sclerosis: A meta-analysis
  42. The Infectious Basis of ACPA-Positive Rheumatoid Arthritis
  43. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
  44. Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis
  45. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment
  46. Disease-related autoantibody profile in patients with systemic sclerosis
  47. From microbiome to infectome in autoimmunity
  48. Loss of C9orf72 function leads to autoimmunity
  49. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases
  50. Human cytomegalovirus (HCMV) UL44 and UL57 specific antibody responses in anti-HCMV-positive patients with systemic sclerosis
  51. Polymorphisms of IL12RB2 May Affect the Natural History of Primary Biliary Cholangitis: A Single Centre Study
  52. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data
  53. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis
  54. Infections as a cause of autoimmune rheumatic diseases
  55. Deciphering the role of DNA methylation in multiple sclerosis: emerging issues
  56. Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis
  57. Assessment of health related quality of life in polish patients with primary biliary cirrhosis
  58. Smoke and autoimmunity: The fire behind the disease
  59. Factors Affecting Exercise Test Performance in Patients After Liver Transplantation
  60. Systemic sclerosis: New evidence re-enforces the role of B cells
  61. Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis
  62. Diagnostic and clinical significance of Crohn’s disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies
  63. Autoantibodies to asialoglycoprotein receptor (ASGPR) in patients with autoimmune liver diseases
  64. Crohn's disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis
  65. Experimental evidence of Migfilin as a new therapeutic target of hepatocellular carcinoma metastasis
  66. Hepatitis B Vaccination and Autoimmunity
  67. Correction: Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA
  68. Infectomics and autoinfectomics: a tool to study infectious-induced autoimmunity
  69. Autoreactivity to isoforms of glycoprotein 2 in inflammatory bowel disease
  70. Early systemic sclerosis—opportunities for treatment
  71. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA
  72. Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing
  73. Evidence of Crohn’s disease-related anti-glycoprotein 2 antibodies in patients with celiac disease
  74. Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma
  75. Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR
  76. Liver and the Biliary Tract
  77. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future
  78. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis
  79. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis—relevance to treatment
  80. Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA
  81. Bioinformatic and immunological analysis reveals lack of support for measles virus related mimicry in Crohn’s disease
  82. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis
  83. Is primary biliary cirrhosis rare or common? The truth lies somewhere in between
  84. Low Serum Vitamin D Levels Are Associated with Severe Histological Features and Poor Response to Therapy in Patients with Autoimmune Hepatitis
  85. Antipancreatic Autoantibodies
  86. Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges
  87. Anti-hnRNP B1 (RA33) Autoantibodies Are Associated with the Clinical Phenotype in Russian Patients with Rheumatoid Arthritis and Systemic Sclerosis
  88. E. coliInduced Experimental Model of Primary Biliary Cirrhosis: At Last
  89. Factors Affecting Health-Related Quality of Life and Physical Activity after Liver Transplantation for Autoimmune and Nonautoimmune Liver Diseases: A Prospective, Single Centre Study
  90. Flow Cytometric Detection of p38 MAPK Phosphorylation and Intracellular Cytokine Expression in Peripheral Blood Subpopulations from Patients with Autoimmune Rheumatic Diseases
  91. Helicobacter pyloriand autoimmune disease: Cause or bystander
  92. Ursodeoxycholic Acid Influences the Expression ofp27kip1but Not FoxO1 in Patients with Non-Cirrhotic Primary Biliary Cirrhosis
  93. Gastric Autoantibodies
  94. Anti-GP2 antibodies in inflammatory bowel disease patients with ileal pouch
  95. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis
  96. Vitamin D in autoimmune liver disease
  97. Bacterial Infections in Liver
  98. Polarisation of Major Histocompatibility Complex II Host Genotype with Pathogenesis of European Brown Hare Syndrome Virus
  99. PR3-ANCA: A promising biomarker for ulcerative colitis with extensive disease
  100. Loss of tolerance to one or two major targets in Crohn's disease or just cross-reactivity?
  101. Standardization of automated interpretation of immunofluorescence tests
  102. Crohn’s disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: Implications for the pathogenesis of the human disease
  103. Infectome: A platform to trace infectious triggers of autoimmunity
  104. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis
  105. Deoxyribonuclease activity of polyclonal IgGs: a putative serological marker in patients with spondyloarthritides
  106. Tracing environmental markers of autoimmunity: introducing the infectome
  107. Liver Immunology
  108. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against “rings and rods”-associated inosine-5′-monophosphate dehydrogenase 2 in viral hepatitis C
  109. p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: Lessons to learn from ANCA vasculitis and pemphigus vulgaris
  110. Glycoprotein 2 Antibodies in Crohn's Disease
  111. Glycoprotein 2 Antibodies in Inflammatory Bowel Disease
  112. CUZD1 and Anti-CUZD1 Antibodies as Markers of Cancer and Inflammatory Bowel Diseases
  113. Development of a Recombinant Cell-Based Indirect Immunofluorescence Assay for the Determination of Autoantibodies against Soluble Liver Antigen in Autoimmune Hepatitis
  114. p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity
  115. Primary Biliary Cirrhosis-Specific Antimitochondrial Antibodies in Neonatal Haemochromatosis
  116. Serum Autoantibodies: From Identification to Clinical Relevance
  117. TRAF1-C5Affects Quality of Life in Patients with Primary Biliary Cirrhosis
  118. The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease
  119. The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis
  120. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: Lost and found
  121. Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What’s New?
  122. Primary biliary cirrhosis and the nuclear pore complex
  123. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease
  124. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis
  125. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature
  126. IgM predominance in autoimmune disease: Genetics and gender
  127. Twin studies in autoimmune disease: Genetics, gender and environment
  128. Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside
  129. Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis
  130. Sex Differences Associated with Primary Biliary Cirrhosis
  131. New Platform Technology for Comprehensive Serological Diagnostics of Autoimmune Diseases
  132. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?
  133. Autoantibodies in Autoimmune Pancreatitis
  134. Epstein-Barr Virus as a Trigger of Autoimmune Liver Diseases
  135. Ileal Inflammation May Trigger the Development of GP2-Specific Pancreatic Autoantibodies in Patients with Crohn’s Disease
  136. TRAF1Gene Polymorphism Correlates with the Titre of Gp210 Antibody in Patients with Primary Biliary Cirrhosis
  137. What Is New in Primary Biliary Cirrhosis?
  138. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies
  139. Human Peripheral Blood Mononuclear Cell Culture for Flow Cytometric Analysis of Phosphorylated Mitogen-Activated Protein Kinases
  140. Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22
  141. Antibodies to glycoprotein 2 (GP2) in patients with inflammatory bowel diseases from UK
  142. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease
  143. Peculiar antibody reactivity to human connexin 37 and its microbial mimics in patients with Crohn's disease
  144. Fetomaternal alloimmunity as a cause of liver disease
  145. Disease-specific autoantibodies in primary biliary cirrhosis
  146. Autoimmunity and Environment: Am I at risk?
  147. The Authors' reply: Figure 1
  148. Immunopathogenesis of primary biliary cirrhosis: an old wives' tale
  149. Primary Biliary Cirrhosis Associated with Systemic Sclerosis: Diagnostic and Clinical Challenges
  150. Primary Biliary Cirrhosis: Family Stories
  151. Type 1 autoimmune pancreatitis
  152. PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis
  153. Primary biliary cirrhosis-specific autoantibodies in patients with systemic sclerosis
  154. Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies
  155. Autoantibodies and their Antigens in Autoimmune Hepatitis
  156. Autoimmune hepatitis
  157. New ELISA for Detecting Primary Biliary Cirrhosis-Specific Antimitochondrial Antibodies
  158. Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s
  159. Primary biliary cirrhosis following lactobacillus vaccination for recurrent vaginitis
  160. Bacteria and Primary Biliary Cirrhosis
  161. LKM1-Positive Type 2 Autoimmune Hepatitis Following Allogenic Hematopoietic Stem-Cell Transplantation
  162. Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: what is the message?
  163. Disease-specific autoantibodies in patients with acute liver failure: The King's College London Experience
  164. Autoimmune liver serology: Current diagnostic and clinical challenges
  165. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis
  166. Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes
  167. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis
  168. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis
  169. How Common Are Connective Tissue Disorders in Patients with Autoimmune Hepatitis?
  170. Development of antimitochondrial antibodies in patients with autoimmune hepatitis: Art of facts or an artifact?
  171. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2
  172. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis
  173. Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: Revealing the unforeseen
  174. Borrelia Burgdorferi: a new self-mimicking trigger in primary biliary cirrhosis
  175. Cytochrome P450 1A2 is a target antigen in hepatitic graft-versus-host disease
  176. Self-mimicking autoimmune domains of hepatitis C virus core antigen
  177. Origin of cross-reactive autoimmunity in primary biliary cirrhosis
  178. Does Cross-Reactivity Between Mycobacterium avium paratuberculosis and Human Intestinal Antigens Characterize Crohn’s Disease?
  179. Polyclonal T-Cell Responses to Cytochrome P450IID6 Are Associated With Disease Activity in Autoimmune Hepatitis Type 2
  180. Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis
  181. Susceptibility to Thyroid Disorders in Hepatitis C
  182. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis
  183. Non-Organ-Specific Autoantibodies in Hepatitis C Virus Infection: Do They Matter?
  184. A Study of Molecular Mimicry and Immunological Cross-reactivity between Hepatitis B Surface Antigen and Myelin Mimics
  185. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic
  186. Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver disease
  187. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis
  188. Primary Biliary Cirrhosis Specific Antinuclear Antibodies in Patients from Spain
  189. Targets of Antibodies to Soluble Liver Antigen in Patients with Autoimmune Hepatitis
  190. Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross‐reactivity
  191. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis
  192. Specificity of anti‐sp100 antibody for primary biliary cirrhosis
  193. Unusual suspects in primary biliary cirrhosis
  194. Antimitochondrial and other autoantibodies
  195. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection
  196. Cytochrome P450 2A6 meets P450 2D6: an enigma of viral infections and autoimmunity
  197. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection
  198. Cytochrome P4502D6193–212: A New Immunodominant Epitope and Target of Virus/Self Cross-Reactivity in Liver Kidney Microsomal Autoantibody Type 1-Positive Liver Disease
  199. Positive markers in AMA-negative PBC
  200. Key Residues of a Major Cytochrome P4502D6 Epitope Are Located on the Surface of the Molecule
  201. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease
  202. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis
  203. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences
  204. Virus, liver and autoimmunity